Literature DB >> 3219799

Three cases of factor I deficiency: the effect of treatment with plasma.

J Møller Rasmussen1, B Teisner, H H Jepsen, S E Svehag, F Knudsen, H Kirstein, M Buhl.   

Abstract

Three patients with congenital factor I deficiency associated with different clinical manifestations are described. Case 1 had one single episode of meningococcal disease, case 2 experienced four episodes of meningococcal disease and several other severe infections, whereas case 3, without known predisposition for infections, died from a subacute immune-complex mediated syndrome, resembling polyarteritis nodosa. Family studies in cases 1 and 2 revealed healthy individuals with factor I concentrations below the lower reference limit, indicating heterozygous carriers. The pedigree analyses were consistent with autosomal codominant inheritance. The estimated minimal frequency of the deficient gene was 0.002. Pedigree analysis was not performed in case 3 but the father and sister was found to be probable heterozygous carriers. Cases 2 and 3 were treated with infusions of freshly frozen plasma (FFP) (40 and 27 ml/kg bodyweight) during acute illness and the immunochemical complement profile was monitored. Following plasma infusion factor I was cleared from the circulation with a half-life of 29-45 h. The plasma infusions induced generation of C3d and C4d, increase in native factor B and C3 concentrations and disappearance of Ba split products. Native C3 and C4 increased to normal concentrations and remained normal till 16 days after the plasma infusions, whereas native factor B decreased to preinfusion levels 8 days after plasma infusion. It is concluded, that congenital factor I deficiency can present with different clinical manifestations and may be more prevalent than hitherto anticipated. Furthermore, infusion of blood products containing small amounts of functional factor I can partly normalize the complement profile, with a more prolonged effect on C3 and C4 than on factor B metabolism.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3219799      PMCID: PMC1541714     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  15 in total

1.  Acute complement activation during an anaphylactoid reaction to blood transfusion and the disappearance rate of C3c and C3d from the circulation.

Authors:  B Teisner; I Brandslund; N Grunnet; L K Hansen; J Thellesen; S E Svehag
Journal:  J Clin Lab Immunol       Date:  1983-10

2.  C3b inactivator deficiency with immune complex manifestations.

Authors:  P Solal-Celigny; M Laviolette; J Hebert; P C Atkins; M Sirois; G Brun; G Lehner-Netsch; J M Delâge
Journal:  Clin Exp Immunol       Date:  1982-01       Impact factor: 4.330

3.  Detection and quantitation of immune complexes with a rapid polyethylene glycol precipitation complement consumption method (PEG-CC).

Authors:  I Brandslund; H C Siersted; J C Jensenius; S E Svehag
Journal:  Methods Enzymol       Date:  1981       Impact factor: 1.600

4.  Preparation of antibodies against the fourth complement component (C4) and development of a direct electroimmunoassay for quantification of C4d.

Authors:  J Folkersen; B Teisner; N E Petersen; R B Sim; E Jessen
Journal:  J Clin Lab Immunol       Date:  1985-03

Review 5.  Complement deficiency states and infection: epidemiology, pathogenesis and consequences of neisserial and other infections in an immune deficiency.

Authors:  S C Ross; P Densen
Journal:  Medicine (Baltimore)       Date:  1984-09       Impact factor: 1.889

6.  Inactivator of the third component of complement as an inhibitor in the properdin pathway.

Authors:  C A Alper; F S Rosen; P J Lachmann
Journal:  Proc Natl Acad Sci U S A       Date:  1972-10       Impact factor: 11.205

7.  Factor I deficiency and C3 nephritic factor: immunochemical findings and association with Neisseria meningitidis infection in two patients.

Authors:  B Teisner; I Brandslund; J Folkersen; J M Rasmussen; L O Poulsen; S E Svehag
Journal:  Scand J Immunol       Date:  1984-10       Impact factor: 3.487

8.  Restoration of complement function in vivo by plasma infusion in factor I (C3b inactivator) deficiency.

Authors:  D J Barrett; M D Boyle
Journal:  J Pediatr       Date:  1984-01       Impact factor: 4.406

9.  Studies in vivo and in vitro on an abnormality in the metabolism of C3 in a patient with increased susceptibility to infection.

Authors:  C A Alper; N Abramson; R B Johnston; J H Jandl; F S Rosen
Journal:  J Clin Invest       Date:  1970-11       Impact factor: 14.808

10.  Quantification of C3dg/Epstein-Barr virus receptors on human B cells and B cell lines.

Authors:  J M Rasmussen; H V Marquart; R Rask; H H Jepsen; S E Svehag
Journal:  Complement       Date:  1988
View more
  13 in total

1.  Recurrent infections in partial complement factor I deficiency: evaluation of three generations of a Brazilian family.

Authors:  A S Grumach; M F Leitão; V G Arruk; M Kirschfink; A Condino-Neto
Journal:  Clin Exp Immunol       Date:  2006-02       Impact factor: 4.330

2.  Complement-activating ability of leucocytes from patients with complement factor I deficiency.

Authors:  H V Marquart; J M Rasmussen; R G Leslie
Journal:  Immunology       Date:  1997-07       Impact factor: 7.397

3.  The molecular basis of hereditary complement factor I deficiency.

Authors:  T J Vyse; B J Morley; I Bartok; E L Theodoridis; K A Davies; A D Webster; M J Walport
Journal:  J Clin Invest       Date:  1996-02-15       Impact factor: 14.808

Review 4.  Complement deficiency and immune complex disease.

Authors:  K A Davies; J A Schifferli; M J Walport
Journal:  Springer Semin Immunopathol       Date:  1994

5.  A missense mutation in factor I (IF) predisposes to atypical haemolytic uraemic syndrome.

Authors:  Joyce Geelen; Koen van den Dries; Anja Roos; Nicole van de Kar; Corrie de Kat Angelino; Ina Klasen; Leo Monnens; Lambertus van den Heuvel
Journal:  Pediatr Nephrol       Date:  2006-11-15       Impact factor: 3.714

6.  Generation of multiple fluid-phase C3b:plasma protein complexes during complement activation: possible implications in C3 glomerulopathies.

Authors:  Mahalakshmi Ramadass; Berhane Ghebrehiwet; Richard J Smith; Richard R Kew
Journal:  J Immunol       Date:  2013-12-23       Impact factor: 5.422

Review 7.  Mutations of complement factor I and potential mechanisms of neuroinflammation in acute hemorrhagic leukoencephalitis.

Authors:  Lori Broderick; Chhavi Gandhi; James L Mueller; Christopher D Putnam; Katayoon Shayan; Patricia C Giclas; Karin S Peterson; Seema S Aceves; Robert M Sheets; Bradley M Peterson; Robert O Newbury; Hal M Hoffman; John F Bastian
Journal:  J Clin Immunol       Date:  2012-08-29       Impact factor: 8.317

8.  Successful long-term outcome after renal transplantation in a patient with atypical haemolytic uremic syndrome with combined membrane cofactor protein CD46 and complement factor I mutations.

Authors:  Werner Lukas Pabst; Thomas J Neuhaus; Samuel Nef; Elena Bresin; Andrea Zingg-Schenk; Giuseppina Spartà
Journal:  Pediatr Nephrol       Date:  2013-03-22       Impact factor: 3.714

9.  Crystal structure and functional characterization of the complement regulator mannose-binding lectin (MBL)/ficolin-associated protein-1 (MAP-1).

Authors:  Mikkel-Ole Skjoedt; Pietro Roversi; Tina Hummelshøj; Yaseelan Palarasah; Anne Rosbjerg; Steven Johnson; Susan M Lea; Peter Garred
Journal:  J Biol Chem       Date:  2012-08-01       Impact factor: 5.157

10.  Cutaneous Vasculitis and Recurrent Infection Caused by Deficiency in Complement Factor I.

Authors:  Sira Nanthapisal; Despina Eleftheriou; Kimberly Gilmour; Valentina Leone; Radhika Ramnath; Ebun Omoyinmi; Ying Hong; Nigel Klein; Paul A Brogan
Journal:  Front Immunol       Date:  2018-04-11       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.